Streetbeat News

Regulatory

NRXP

NRx Pharmaceuticals has published a paper in the American Journal of Clinical Psychopharmacology detailing a new training and monitoring methodology that improves interrater reliability in depression ratings for clinical trials. This has positive implications for future trials of NRX-101 and similar medications.

Portfolio Pulse from

November 25, 2024 | 1:15 pm

M

Macy's reported a drop in quarterly sales and delayed its full earnings release due to an accounting issue related to erroneous reporting of delivery expenses by an employee.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

SA

Seabridge Gold Inc.'s KSM Project faces a legal challenge from the Tsetsaut Skii km Lax Ha, an Indigenous group, which has filed a petition in the British Columbia Supreme Court. The group seeks a judicial review of the project's 'substantially started' status, impacting Seabridge's operations.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

FAS

Following the 2024 U.S. presidential election, markets are preparing for a second Trump administration, with potential new financial policies and regulations. The S&P 500 has risen by 3.2% since the election.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

EW

Bernstein Liebhard LLP has issued an investor alert for Edwards Lifesciences Corporation (NYSE: EW), reminding investors of an upcoming deadline. This alert may pertain to legal or regulatory matters involving the company.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

NDAQ

NOCN

noco-noco Inc. has received a delisting notice from Nasdaq due to non-compliance with listing requirements. The company plans to appeal the decision and is working to regain compliance. The delisting will not affect its operations.

Portfolio Pulse from

November 25, 2024 | 1:00 pm

GLW

Corning has proposed changes to its contract clauses to address the European Union's antitrust concerns over alleged exclusive dealing, aiming to settle the ongoing investigation.

Portfolio Pulse from

November 25, 2024 | 12:45 pm

AVXL

Anavex Life Sciences announced the acceptance of a peer-reviewed manuscript on their drug Blarcamesine for Alzheimer's treatment in a specialized journal. This highlights the progress of their Phase IIb/III trial results.

Portfolio Pulse from

November 25, 2024 | 12:45 pm

PTN

Palatin Technologies has completed patient enrollment for its Phase 2 study of PL8177, an orally administered melanocortin agonist, for treating ulcerative colitis. The treatment aims to offer a safer alternative to current therapies. Results are expected in Q1 2025.

Portfolio Pulse from

November 25, 2024 | 12:45 pm

BHVN

Biohaven's taldefgrobep alpha showed improvements in motor function for SMA patients but did not achieve statistical significance in the primary outcome at Week 48. Efficacy signals were noted in specific subgroups.

Portfolio Pulse from

November 25, 2024 | 12:45 pm